Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial

Matti Annala, Simon Fu, Jack V. W. Bacon, Joonatan Sipola, Nayyer Iqbal, Cristiano Ferrario, Michael Ong, Deepa Wadhwa, Sébastien J. Hotte, Gregory Lo, Ben Tran, Lori Wood, Joel Roger Gingerich, Scott North, Carmel Pezaro, Joseph D. Ruether, Srikala S. Sridhar, Heini Kallio, Daniel Khalaf, Amanda Wong, Kevin Beja, Elena Schönlau, Sinja Taavitsainen, Matti Nykter, Gillian Vandekerkhove, Arun Azad, Alexander W. Wyatt, K.N. Chi